OBICETRAPIB TARGETS ALL ATHEROGENIC LIPOPROTEINS BEYOND LDL-C
Therapeutic Area: Kidney Disease Background: Despite reductions in low-density lipoprotein cholesterol (LDL-C) with statin and non-statin lipid-lowering therapies, a large proportion of cardiovascular disease (CVD) risk remains. An investigation of 8 large CV outcome trials with statins demonstrated...
Saved in:
Main Author: | Michael Davidson, MD (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
VLDL receptor gene therapy for reducing atherogenic lipoproteins
by: Ronald M. Krauss, et al.
Published: (2023) -
Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
by: Jelena Vekic, et al.
Published: (2022) -
Electronegative LDL from Rabbits Fed with Atherogenic Diet Is Highly Proinflammatory
by: Po-Yuan Chang, et al.
Published: (2019) -
Discordantly normal ApoB relative to elevated LDL-C in persons with metabolic disorders: A marker of atherogenic heterogeneity
by: Alexander C. Razavi, et al.
Published: (2021) -
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
by: Maya Safarova, et al.
Published: (2024)